NASDAQ:SONN Sonnet BioTherapeutics Q2 2024 Earnings Report $4.22 -0.35 (-7.66%) Closing price 04:00 PM EasternExtended Trading$4.32 +0.10 (+2.25%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Sonnet BioTherapeutics EPS ResultsActual EPS$0.56Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ASonnet BioTherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASonnet BioTherapeutics Announcement DetailsQuarterQ2 2024Date5/14/2024TimeN/AConference Call DateTuesday, May 14, 2024Conference Call Time7:00AM ETUpcoming EarningsSonnet BioTherapeutics' Q3 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Tuesday, August 12, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Sonnet BioTherapeutics Earnings HeadlinesSolana-based treasury model goes global as DeFi Development launches franchiseJuly 17, 2025 | msn.comWLFI tokens to become tradable after World Liberty holders’ voteJuly 17, 2025 | msn.comI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits.July 24 at 2:00 AM | Timothy Sykes (Ad)Sonnet BioTherapeutics Stock Jumps 82% After Deal With Rorschach I: Retail Stays ExuberantJuly 15, 2025 | msn.comSonnet BioTherapeutics Shares Climb After Plan to Transfer Into Public Crypto Treasury Co.July 14, 2025 | marketwatch.comHyperliquid Price Forecast: HYPE eyes gains following Sonnet BioTherapeutics' rebrandJuly 14, 2025 | fxstreet.comSee More Sonnet BioTherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sonnet BioTherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sonnet BioTherapeutics and other key companies, straight to your email. Email Address About Sonnet BioTherapeuticsSonnet BioTherapeutics (NASDAQ:SONN), a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.View Sonnet BioTherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings?Microsoft’s AI Bet Faces a Major Test This Earnings SeasonAmazon Stock Rally Hits New Highs: Buy Into Earnings?TSLA Earnings Week: Can Tesla Break Through $350?Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets Upcoming Earnings Charter Communications (7/25/2025)AON (7/25/2025)ENI (7/25/2025)HCA Healthcare (7/25/2025)ICICI Bank (7/25/2025)NatWest Group (7/25/2025)Phillips 66 (7/25/2025)Southern Copper (7/25/2025)Cadence Design Systems (7/28/2025)Enterprise Products Partners (7/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
